Abstract
Castrate resistant prostate cancer remains a significant problem, despite the introduction of many new anticancer agents in recent years. Of importance, establishing true castration resistance, confirmed biochemically, is a sine qua non of effective management. It should also be recognized that stage migration has occurred, with more patients being offered treatment for PSA-only castration-resistant disease, and with the increased radiological surveillance of patients after definitive local treatment, and the goal posts have widened due to increased emphasis on patient-reported outcomes and progression-free survival. That said, it is clear that, in addition to established cytotoxic agents, several new options of systemic therapy are active in castrate resistant prostate cancer, including ixabepilone, cabazitaxel, cabozantanib, and the current focus seems to be shifting somewhat from cytotoxic to targeted therapeutics.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol. 1985;3:1013–21.
Raghavan D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol. 1988;15:371–89.
Petrylak D, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20.
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
Slack NH. Results of chemotherapy protocols of the US National Prostatic Cancer Project (NPCP). Clin Oncol. 1983;2:441–59.
Kelly WK, Scher HI, Mazumdar M. Prostate specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993;11:607–15.
Sridhara R, Eisenberger MA, Sinibaldi V, et al. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol. 1995;13:2944–53.
Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461–7.
Petrylak D, Ankerst DP, Jiang CS, et al. Evaluation of post treatment PSA declines for surrogacy using Prentice’s criteria in patients treated on SWOG 99–16. J Natl Cancer Inst. 2006;98:516–21.
Economos C, Morrissey C, Vessella RL. Circulating tumor cells as a marker of response: implications for determining treatment efficacy and evaluating new agents. Curr Opin Urol. 2012;22:190–6.
DeBono JS, Scher HI, Montgomery BR, et al. Circulating tumor cells (CTC) predict survival benefit from treatment in metastatic castration resistant prostate cancer (CRPC). Clin Cancer Res. 2008;14:6302–9.
Scher HI, Jia X, de Bono JS, et al. Circulating tumor cells as prognostic markers in progressive castration-resistant prostate cancer: a re-analysis of IMMC38 data. Lancet Oncol. 2009;10:233–9.
Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654–63.
Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.
Browman GP. Science, language, intuition, and the many meanings of quality of life. J Clin Oncol. 1999;17:1651–3.
Raghavan D, Coorey G, Rosen M, et al. Management of hormone-resistant prostate cancer: an Australian trial. Semin Oncol. 1996;23 Suppl 14:20–3.
Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;17:2506–13.
Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21:3335–42.
Berry W, Dakhil S, Modiano M, et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose alone in patients with asympotomatic, hormone refractory prostate cancer. J Urol. 2002;168:2451–3.
Raghavan D, Brandes LJ, Klapp K, et al. Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases. J Urol. 2005;174:1808–13.
Beer T, Raghavan D. Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder. Prostate. 2000;45:184–93.
Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1997;15:3156–63.
Savarese D, Taplin ME, Halabi S, et al. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B trial 9780. Semin Oncol. 1999;26 suppl 17:39–44.
Petrylak DP, Macarthur R, O’Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone refractory prostate cancer. Semin Oncol. 1999;26(5 suppl 17):28–33.
Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44–53.
Urakami S, Igawa M, Kikuno K, et al. Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer. J Urol. 2002;168:2444–50.
Raghavan D. Novel therapies for advanced prostate cancer – have we widened the goal posts too far? Ann Oncol. 2012;23:2473–5.
Fizazi K, LeMaitre A, Hudes G, et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007;8:994–1000.
Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15:723–30.
de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet Oncol. 2010;376:1147–54.
Galsky MD, Small EJ, Oh WK, et al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005;23:1439–46.
Hussain A, DiPaola RS, Baron AD, et al. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol. 2009;20:492–7.
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.
Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012;104:273–9.
Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL 184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29:2660–6.
Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31:412–9.
Wang J, Halford S, Rigg A, et al. Adjuvant mitozantrone chemotherapy in advanced prostate cancer. BJU Int. 2000;86:675–80.
Flaig TW, Tangen CM, Hussain MH, et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol. 2008;26:1532–6.
Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology. 2004;63:1138–42.
Shepard DR, Dreicer R, Garcia J, et al. Phase II trial of NAB-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol. 2009;181:1672–7.
Dreicer R, Garcia J, Rini B, et al. A randomized, double-blind, placebo-controlled, phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. Invest New Drugs. 2013;31:1044–50.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag London
About this chapter
Cite this chapter
Raghavan, D., Chai, S., Mahoney, J. (2015). Castrate Resistant Prostate Cancer: Systemic Chemotherapy and a System Problem. In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_49
Download citation
DOI: https://doi.org/10.1007/978-0-85729-482-1_49
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-481-4
Online ISBN: 978-0-85729-482-1
eBook Packages: MedicineMedicine (R0)